Theradiag (ALTER)

Executive Summary

Theradiag is a French biotechnology company specializing in in vitro diagnostics (IVD) for therapeutic monitoring and personalized medicine. Founded in 1987 and publicly traded on Euronext Growth (ticker: ALTER), the company develops and markets tests for autoimmune diseases, cancer, and infectious diseases. Theradiag's core strength lies in its multiplex immunoassay technology, which enables simultaneous detection of multiple biomarkers from a single sample, supporting early diagnosis and treatment optimization. In autoimmune diseases, its flagship product, the FIDIS™ line, allows for quantitative measurement of autoantibodies. The company is expanding its pipeline into oncology and infectious disease monitoring, aiming to address unmet needs in therapy management. Despite its niche focus, Theradiag faces competition from larger diagnostics players and must navigate regulatory complexities. Financially, it remains a small-cap with limited resources, but its long track record and European market presence provide a stable foundation for growth.

Upcoming Catalysts (preview)

• Q1 2026European launch of new oncology monitoring test60% success
• Q4 2025Partnership with major pharma for companion diagnostics40% success
• Q3 2026Positive H1 2026 financial results or new product approval announcement50% success